LakeShore Biopharma Co (LakeShore Biopharma Co) Inventories, Finished Goods : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Inventories, Finished Goods?

LakeShore Biopharma Co's quarterly finished goods increased from Sep. 2022 ($10.15 Mil) to Mar. 2023 ($11.38 Mil) but then declined from Mar. 2023 ($11.38 Mil) to Sep. 2023 ($0.00 Mil).

LakeShore Biopharma Co's annual finished goods declined from Mar. 2021 ($12.05 Mil) to Mar. 2022 ($11.55 Mil) and declined from Mar. 2022 ($11.55 Mil) to Mar. 2023 ($11.38 Mil).

LakeShore Biopharma Co Inventories, Finished Goods Historical Data

The historical data trend for LakeShore Biopharma Co's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Inventories, Finished Goods Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Inventories, Finished Goods

12.05

11.55

11.38

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Inventories, Finished Goods	Get a 7-Day Free Trial			-	11.55	10.15	11.38	-

LakeShore Biopharma Co Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.